A Decade-Long Review of the Virulence, Resistance, and Epidemiological Risks of Klebsiella pneumoniae in ICUs

• Published in: Microorganisms (Basel) Vol. 12; no. 12; p. 2548
• Main Authors: Chen, Tao-An, Chuang, Ya-Ting, Lin, Chieh-Hui
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.12.2024; MDPI
• Subjects: Antibiotics; Antimicrobial agents; Bacteria; Bacterial infections; Bacterial pneumonia; Biofilms; carbapenem-resistant organisms; Carbapenems; Comorbidity; Development and progression; Disease control; Drug resistance; Epidemiology; Genotype & phenotype; Health aspects; Health services; Hospital patients; Hospitals; Infections; Intensive care units; Klebsiella; Klebsiella pneumoniae; Mortality; Multidrug resistance; Opportunist infection; Pathogens; Pneumonia; Review; Vaccine development; Virulence; Virulence factors; China; Taiwan; multidrug resistance; carbapenem-resistant organisms; Klebsiella pneumoniae; virulence factors; intensive care units
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms12122548

Klebsiella pneumoniae, a major opportunistic pathogen, causes severe infections in both community and healthcare settings, especially in intensive care units (ICUs), where multidrug-resistant (MDR) strains, such as carbapenem-resistant K. pneumoniae (CRKP), pose significant treatment challenges. The rise in hypervirulent K. pneumoniae (hvKP) with enhanced virulence factors complicates management further. The ST11 clone, prevalent in China, exhibits both resistance and virulence traits, contributing to hospital outbreaks. ICU patients, particularly those with comorbidities or prior antibiotic exposure, are at higher risk. Treatment is complicated by limited antibiotic options and the increasing prevalence of polymicrobial infections, which involve resistant pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii. Combination therapies offer some promise, but mortality rates remain high, and resistance to last-resort antibiotics is growing. Infection control measures and personalized treatment plans are critical, alongside the urgent need for vaccine development to combat the rising threat of K. pneumoniae, particularly in vulnerable populations. Effective management requires improved diagnostic tools, antimicrobial stewardship, and innovative treatment strategies to reduce the burden of this pathogen, especially in resource-limited settings. This review aims to provide a comprehensive analysis of the virulence, resistance, and epidemiological risks of K. pneumoniae in ICUs over the past decade, highlighting the ongoing challenges and the need for continued efforts to combat this growing threat.